IDH1 and myeloid neoplasm: The phase Ib/II VIALE-A study (NCT03471260) evaluated the use of ivosidenib and venetoclax with or without azacitidine as frontline therapy in relapsed/refractory patients and showed that it was safe in IDH1-mutated myeloid malignancies and appeared to escape mechanisms of resistance that have been observed with the use of single-agent IDH inhibitors [99].